

## TO ALL CANADIAN MPN PATIENTS **UPDATE March 25, 2025**

We understand that many of you have been waiting for updates regarding the Pegasys drug shortage in Canada. Currently, Pegasys is categorized as a Tier 3 shortage in Canada, which is the most serious level of drug shortage recognized by Health Canada.

We are pleased to announce, along with LLSC and FORUS Therapeutics, that as of March 15, 2025, Health Canada **has permitted the exceptional, temporary importation and sale of US-authorized BESREMi** (ropeginterferon alfa-2b-njft) injection.

Additional information on BESREMi and the switchover from Pegasys can be found on the FORUS Therapeutics website at [www.besremiei.com](http://www.besremiei.com) and official notification details from Health Canada can be found in English [here](#) and in French [here](#).

The intent is for patients with ET, PV, or MF, who are currently on PEGASYS, to be moved onto BESREMi by their physician when it becomes necessary, due the shortage of PEGASYS.

Patients receiving BESREMi will initially need to see their physician *in-person* to be guided through the dosing instructions. Each patient, in consultation with their medical professional, will be given regular monitoring instructions and any side effects need to be reported immediately to their medical professional. In collaboration with Dr. Sirhan, President of the Canadian MPN Group, the equitable distribution of the available Pegasys supply across provinces has occurred, with prioritization for exceptional individuals.

For those currently receiving or about to be prescribed Pegasys with payment through private health insurance, contact the Drug Access Navigator at your treatment centre to assist you in applying for BESREMi.

**Many of you have been proactive in contacting your physicians, however if you have not, this is the time to do so.**

We will continue to meet knowing there will be information to be shared as it becomes available. If you have any questions, again, please refer to the above website links and your physician. If, after that, you still have questions, you may direct them to us, and we will attempt to answer them. Thank you for your patience and understanding.

Warm Regards,

Patti Saluk, Board Chair  
John Clark, Advocacy Chair  
Canadian MPN Network  
[patti.saluk@canadianmpnnetwork.ca](mailto:patti.saluk@canadianmpnnetwork.ca)

Christina Sit, Manager,  
Community Strategic Partnership  
Leukemia & Lymphoma Society of Canada  
[Christina.Sit@lls.org](mailto:Christina.Sit@lls.org)

